Oruka Therapeutics (ORKA) Net Cash Flow Growth (3y) (2013 - 2026)
Oruka Therapeutics (ORKA) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 32.17% |
| 10 | Oruka Therapeutics | 952.09 Mn | 120.94 Mn | - | 53.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.55% |
| Dec 31, 2025 | -209.60% |
| Sep 30, 2025 | 131.19% |
| Jun 30, 2025 | -91.05% |
| Mar 31, 2025 | 92.34% |
| Dec 31, 2024 | -313.12% |
| Sep 30, 2024 | 336.26% |
| Jun 30, 2024 | -50.05% |
| Mar 31, 2024 | 15.81% |
| Dec 31, 2023 | 19.50% |
| Sep 30, 2023 | -26.86% |
| Jun 30, 2023 | 12.75% |
| Mar 31, 2023 | 1.89% |
| Dec 31, 2022 | -5.23% |
| Sep 30, 2022 | -98.58% |
| Jun 30, 2022 | -49.45% |
| Mar 31, 2022 | -71.86% |
| Dec 31, 2021 | -50.68% |
| Sep 30, 2021 | -45.70% |
| Jun 30, 2021 | -14.93% |